Journal Article

Superiority of Protease Inhibitors over Nonnucleoside Reverse-Transcriptase Inhibitors when Highly Active Antiretroviral Therapy Is Resumed after Treatment Interruption

Pablo Barreiro, Carmen de Mendoza, Juan González-Lahoz and Vincent Soriano

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 41, issue 6, pages 897-900
Published in print September 2005 | ISSN: 1058-4838
Published online September 2005 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/432887
Superiority of Protease Inhibitors over Nonnucleoside Reverse-Transcriptase Inhibitors when Highly Active Antiretroviral Therapy Is Resumed after Treatment Interruption

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Forty-five human immunodeficiency virus (HIV)—infected patients stopped taking treatment but resumed taking it thereafter. All 11 who resumed treatment with their prior protease inhibitor (PI)—based regimen reattained an undetectable virus load, whereas this occurred for only 15 (44%) of 34 patients who resumed nonnucleoside reverse-transcriptase inhibitor (NNRTI)—based treatment (P < .001). Distinct pharmacokinetics and resistance barriers may result in different performances for PIs and NNRTIs after treatment interruptions.

Journal Article.  2026 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.